Company Overview

Zomedica Corp. is a veterinary health company focused on companion animal diagnostics and therapeutic products for dogs and cats. The company operates within the animal health and veterinary technology industries, developing and commercializing products intended for use by veterinarians in clinical settings. Its primary revenue drivers are diagnostic testing platforms, consumables tied to those platforms, and therapeutic medical devices used in veterinary practices. Public filings and company disclosures identify recurring revenue from assay cartridges, diagnostics consumables, and therapeutic procedure utilization as important components of its business model.

The company’s portfolio has evolved through internal development and acquisitions. Zomedica was originally organized to commercialize point-of-care diagnostic products for veterinarians, with its flagship TRUFORMA diagnostic platform representing an early commercialization milestone. Over time, the company expanded into therapeutic and imaging-related veterinary technologies through acquisitions, including Pulse Veterinary Technologies, Assisi Animal Health, VetGuardian, and Structured Monitoring Products. This transition broadened the company from a diagnostics-focused business into a diversified veterinary health platform serving companion animal clinics and specialty veterinary providers across multiple treatment categories.

Business Operations

Zomedica generates revenue through several veterinary product lines spanning diagnostics, therapeutics, monitoring, and imaging support technologies. Its operations include the TRUFORMA diagnostic platform and related assays, the PulseVet shock wave therapy systems used for equine and companion animal treatments, the Assisi Loop and related targeted pulsed electromagnetic field products from Assisi Animal Health, and patient monitoring systems associated with VetGuardian and Structured Monitoring Products. Revenue is derived from direct equipment sales, consumables, recurring therapy usage, and veterinary practice support products.

The company primarily operates in the United States while also maintaining international distribution relationships in selected markets. Zomedica controls intellectual property associated with several of its veterinary technologies and has emphasized integrated veterinary clinic solutions through its acquisitions. Public disclosures indicate that subsidiaries operate under the broader Zomedica corporate structure while maintaining specialized product focus areas. The company has also used third-party manufacturing, distribution arrangements, and veterinary channel partnerships to support commercialization efforts.

Strategic Position & Investments

Zomedica’s strategic direction has centered on building a diversified companion animal health platform through acquisitions and product expansion. Major investments have included the acquisitions of Pulse Veterinary Technologies in 2021, Assisi Animal Health in 2022, and later additions including VetGuardian and Structured Monitoring Products. These transactions expanded the company into non-invasive therapeutics, pain management, patient monitoring, and veterinary workflow technologies. Company filings describe a strategy focused on recurring revenue opportunities and cross-selling products into veterinary clinics already using other Zomedica solutions.

The company has positioned itself within higher-growth areas of animal health, particularly companion animal diagnostics and therapeutic technologies. Its activities reflect broader veterinary industry trends toward advanced in-clinic diagnostics, non-pharmaceutical therapies, and digitally enabled patient monitoring. Zomedica has also emphasized maintaining a strong cash position relative to many small-cap veterinary technology peers, though public filings indicate continued operating losses and ongoing commercialization investments. Data regarding long-term profitability timelines remains inconclusive based on available public sources.

Geographic Footprint

Zomedica is headquartered in Ann Arbor, Michigan, and conducts the majority of its commercial operations in North America, particularly the United States veterinary market. The company’s products are marketed primarily to companion animal veterinary clinics, specialty hospitals, and select equine treatment providers. Public disclosures identify the U.S. as the company’s dominant source of revenue and operational activity.

Internationally, Zomedica has pursued distribution relationships and selected commercial expansion opportunities outside the United States. Its technologies, particularly shock wave therapy systems associated with PulseVet, have had visibility in additional veterinary markets through distributor networks. While the company has some international operational exposure, available filings indicate that its global footprint remains substantially smaller than its domestic business presence.

Leadership & Governance

Zomedica’s leadership team has focused on expanding the company through acquisitions, commercialization of veterinary technologies, and operational integration of acquired businesses. The company’s governance structure reflects a publicly traded animal health company with oversight from an independent board and executive leadership team. Strategic messaging from management has consistently emphasized building a broad veterinary health platform with recurring revenue characteristics and clinically differentiated technologies.

Key executives and leaders include:

• Larry Heaton – Chief Executive Officer
• Peter Donato – Chief Financial Officer
• Stephanie Morley – Vice President, General Counsel and Corporate Secretary
• Ashley Hennings – Vice President of People and Culture

The company was originally founded by veterinary and biotechnology-focused entrepreneurs prior to its public market development and subsequent strategic transformation through acquisitions. Leadership commentary in SEC filings and investor materials has emphasized disciplined capital allocation, veterinary market expansion, and integration of complementary animal health technologies.